Invesco Exchange-Traded Self-Indexed Fund Trust has released its latest financial report, revealing key metrics that underscore its standing in the investment industry. The report, filed on October 30, 2026, details the fund's total assets and liabilities, providing insight into its financial health and investment strategies.
As of August 31, 2026, Invesco's total assets were reported at approximately $4.89 billion, with total liabilities around $312.9 million. This results in net assets of about $4.58 billion, indicating a solid financial position for the fund. The filing emphasizes the fund's focus on corporate bonds, particularly through its Invesco BulletShares 2027 Corporate Bond ETF.
Background
Invesco Exchange-Traded Self-Indexed Fund Trust, identified by CIK 0001657201, operates as an investment entity. The trust is based in Downers Grove, Illinois, and primarily engages in managing exchange-traded funds (ETFs). The firm has undergone name changes in the past, previously known as PowerShares Exchange-Traded Self-Indexed Fund Trust.
What the Filing Says
The recent filing, accession number 0001657201-26-000779, provides a snapshot of the fund's financial status as of August 31, 2026. It states, "The fund's total assets are approximately $4,889,045,710.92, with liabilities totaling $312,924,055.26." This information is crucial for investors and stakeholders to assess the fund's performance and strategy.
Impact
This financial update may influence various stakeholders, including investors, analysts, and competitors in the investment sector. The report highlights Invesco's strategic focus on corporate bonds, which may affect investor decisions and market dynamics within the ETF space. Notably, competitors such as J.P. Morgan and Goldman Sachs are also active in this market, making the competitive landscape significant.
What's Next
The filing does not specify what happens next for Invesco Exchange-Traded Self-Indexed Fund Trust, leaving stakeholders to anticipate future updates or strategic moves from the firm.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






